SCHEMBL5136000

SCHEMBL5136000

CCCCN(Cc1ccc(CC)cc1)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.42
ATP4B P51164 4/20 0.42
C5AR1 P21730 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
BCHE P06276 3/20 0.40
HSD17B10 Q99714 1/20 0.39
DRD2 P14416 3/20 0.39
DRD3 P35462 3/20 0.39
MAPT P10636 1/20 0.39
CNR2 P34972 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4B Q07343 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135871 0.97 ATP4A (0.44) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5137164 0.96 C5AR1 (0.44) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5136763 0.94 KDM4E (0.43) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5136185 0.94 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRGAA
SCHEMBL5070096 0.94 ATP4A (0.50) ATP4AATP4BDRD2DRD3
SCHEMBL5075063 0.93 TP53 (0.42) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5134726 0.93 ATP4A (0.41) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5136633 0.93 ATP4A (0.45) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5135329 0.93 TP53 (0.46) ATP4AATP4BC5AR1KDM4EALDH1A1
SCHEMBL5144432 0.92 C5AR1 (0.44) ATP4AATP4BC5AR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed